Octreotide
Generic version of injectable acromegaly treatment launches in US
A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release.
VIDEO: Data shed new light on treatments for acromegaly, Cushing’s disease
BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.
Positive response to oral octreotide seen for adults with acromegaly across three trials
BOSTON — The majority of people with acromegaly receiving oral octreotide achieve a biochemical response, regardless of their baseline insulin-like growth factor I level, according to data from a post hoc analysis.
Once-monthly octreotide provides sustained acromegaly control with fewer injections
BOSTON — Adults with acromegaly previously controlled with standard of care experienced similar disease control with once-monthly injectable octreotide at 24 and 52 weeks, with no serious adverse events, data presented at ENDO 2024 show.
Octreotide acetate injections voluntarily recalled due to glass particles
Octreotide acetate injection 500 µg/mL has been voluntarily recalled due to the presence of glass particles in a syringe, according to a press release.
Oral octreotide efficacy maintained in more than 90% of adults with acromegaly at 3 years
ATLANTA — More than 90% of adults with acromegaly remained responders to oral octreotide 3 years after initiating treatment, according to findings from the MPOWERED open-label extension study presented at ENDO 2022.
Oral acromegaly therapy maintains efficacy for most initial responders at 62 weeks
Nearly all responders to a 26-week course of oral octreotide maintained a biochemical response and symptomatic control of acromegaly at 62 weeks, according to data from the MPOWERED trial.
Oral octreotide associated with better quality of life, work productivity in acromegaly
Adults with acromegaly reported improved quality of life and more work productivity after transitioning from injectable somatostatin receptor ligands to oral octreotide capsules, according to MPOWERED phase 3 trial data.
Oral octreotide provides sustained biochemical control in acromegaly
Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide maintained response for an additional 48 weeks with no new safety signals observed, data from an open-label extension study show.
Oral acromegaly capsule similar to injection therapy in top-line data
An oral form of the somatostatin analogue octreotide was similar to injection therapy as a long-term maintenance treatment for adults with acromegaly, according to top-line data from the MPOWERED trial.